Drug intelligence / Profile preview

Teosyal RHA 3

Development stage
Unknown
Lead developer
Teoxane
Administration
Intradermal
01

Overview

Teosyal RHA 3 is an injectable dermal filler developed by Teoxane Laboratories, composed of cross-linked hyaluronic acid (23 mg/mL) and lidocaine (0.3%). It is part of the Resilient Hyaluronic Acid (RHA) collection, which utilizes a proprietary cross-linking technology designed to preserve the natural long chains of hyaluronic acid. This formulation allows the gel to adapt to dynamic facial movements while providing structural support and volume restoration. Teosyal RHA 3 is specifically indicated for the correction of medium to deep wrinkles, such as nasolabial folds, marionette lines, and deep skin creases, as well as for lip augmentation. The product is injected into the mid-to-deep dermis and typically provides results lasting between 9 to 18 months. In the United States, the RHA collection is distributed exclusively by Revance Therapeutics and has received FDA approval for the treatment of dynamic facial wrinkles and folds.

Brand names
Teosyal RHA 3RHA 3RHA3RHA-3
Other names
Teosyal Resilient Hyaluronic Acid 3
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Teosyal RHA 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teosyal RHA 3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call